Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Synergy Spine Solutions Highlights Superior 2-Year IDE Synergy Disc Outcomes Over ACDF: As reported by OrthoSpineNews, two-year IDE clinical trial data presented at SMISS demonstrated an 87.1% composite success rate for the lordotic Synergy Disc® compared to 56.6% for fusion, with significant improvements in C2–C7 sagittal alignment.
• Fusion Orthopedics Launches FibFix Fibula Nail System at AOFAS and OTA 2026: Reported in OrthoSpineNews, Fusion Orthopedics commercially launched its FibFix™ intramedullary nail platform featuring Tornado Thread proximal purchase and integrated syndesmotic fixation for distal fibula fractures.
• Onkos Surgical Expands NanoCept Antibacterial Coating to Total Femoral Replacements: Reported by OrthoSpineNews, Onkos Surgical announced the commercial release of its ELEOS™ Total Femoral Adapter coated with NanoCept® antibacterial technology to combat prosthetic joint infections in massive limb salvage reconstructions.
• Aevumed SUPERCYNCH Button System Cleared: Aevumed, Inc. secured FDA 510(k) clearance (K253065) for the Aevumed SUPERCYNCH™ Button System indicated for soft tissue to bone reattachment in tendon and ligament fixation.
• Arthrex DynaNite Staples Cleared: Arthrex, Inc. received FDA 510(k) clearance (K262451) for Arthrex DynaNite® Staples providing nitinol compressive internal fixation for fractures, osteotomies, and arthrodesis in the hand, foot, and ankle.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Orthobiologics

Synergy Spine Solutions — Two-Year IDE Data Demonstrates Superiority of Lordotic Synergy Disc Over ACDF at SMISS

• Summary: Synergy Spine Solutions presented two-year primary endpoint data from its U.S. IDE clinical trial demonstrating that the Synergy Disc achieved an 87.1% composite clinical success rate, demonstrating statistical superiority over anterior cervical discectomy and fusion (56.6%, p < 0.0001). Patients experienced a 92% Neck Disability Index responder rate alongside marked reductions in neck and arm pain. Segmental and global alignment significantly improved, with C2–C7 lordosis increasing by 27% and overall mean disc angle improving by 8.6 degrees at 24 months.
• Key Details:
  • Device/System Name: Synergy Disc®
  • Status: Two-Year IDE Clinical Trial Results (SMISS Annual Forum)
  • Clinical Significance: Addresses cervical sagittal alignment loss in disc arthroplasty via a built-in 6-degree lordotic core and nickel-free titanium alloy endplates, combining physiological motion preservation with lordosis correction.
• Original Source: OrthoSpineNews

Trauma & Extremities

Fusion Orthopedics — Fusion Orthopedics Launches the FibFix Fibula Nail System at AOFAS and OTA 2026

• Summary: Fusion Orthopedics announced the commercial launch of the FibFix Fibula Nail System, a dedicated intramedullary fixation platform for distal fibular fractures. The system incorporates a Dual Helix Tornado Thread design for robust proximal purchase, a flexible titanium FlexZone shaft, and four 2.8mm distal interlock holes to stabilize Weber A and B fractures. The implant also provides three dedicated syndesmotic fixation holes supporting either rigid syndesmosis screws or the flexible Fusion Bolo Button Syndesmosis Rope System.
• Key Details:
  • Device/System Name: FibFix™ Fibula Nail System
  • Status: Commercial Product Launch (AOFAS & OTA 2026)
  • Clinical Significance: Delivers a minimally invasive, soft-tissue-sparing intramedullary alternative to traditional lateral plating in compromised or osteoporotic distal fibula fractures, reducing wound dehiscence risk while providing rigid syndesmotic stability.
• Original Source: OrthoSpineNews

Joint Reconstruction

Onkos Surgical — Onkos Surgical Expands Access to NanoCept Antibacterial Technology for Total Femoral Replacements

• Summary: Onkos Surgical announced the commercial release of its ELEOS Total Femoral Adapter coated with NanoCept Antibacterial Technology, expanding antibacterial implant options to massive limb salvage reconstructions. First produced at Onkos's newly opened NanoCept Innovation Center in Bridgewater, NJ, the technology utilizes an FDA De Novo-authorized coating that demonstrated a 99.999% (5-log) bacterial kill rate in pre-clinical testing against common operating room pathogens.
• Key Details:
  • Device/System Name: ELEOS™ Total Femoral Adapter with NanoCept® Antibacterial Technology
  • Status: Commercial Market Release
  • Clinical Significance: Mitigates early bacterial colonization in high-risk, immunocompromised oncologic and complex revision total femur patients, where prosthetic joint infection carries catastrophic morbidity and high amputation rates.
• Original Source: OrthoSpineNews

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.